Eyeing the prize: Opthea

Alan Kohler speaks with Dr Megan Baldwin, the CEO and Managing Director of Opthea, regarding their OPT-302 molecule, which deals with age-related macular degeneration and diabetic oedema.

Become a TCI Community Member Now

Stay up to date and make better informed decisions.
Get access to all this exclusive content and so much more every week!

  • $1 for the first month
  • $25/month membership
  • Cancel anytime, no lock in contract
  • Access to Private Facebook group
  • Smartphone App (coming soon)